Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 853-861

  Levison, Julie H ^a   Orrell, Catherine ^b   Losina, Elena ^a,c   Lu, Zhigang ^a,d   Freedberg, Kenneth A ^a,c,d   Wood, Robin ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SOUTH AFRICA; THERAPY DELAY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052940976     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1819     Document Type: Article

References (47)

1. World Health Organization. Progress on global access to HIV antiretroviral therapy a report on '3x5' and beyond. Geneva: World Health Organization 2006. (Accessed 11 May 2011.) Available from http://www.who.int/ hiv/ progreport2006-en.pdf
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Geneva WHO, UNICEF, UNAIDS 2008. (Accessed 11 May 2011.) Available from http://www.who.int/ hiv/pub/towards-universal-access- report-2008.pdf
3. World Health Organization. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach. Geneva: World Health Organization, HIV Department 2007. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/pub/meetingreports/Second-Line- Antiretroviral.pdf
4. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007; 44:453-455. (Pubitemid 46147632)
5. Boyd MA, Cooper DA. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS 2007; 21 Suppl 4:S55-S63. (Pubitemid 47051750)
6. Elliott JH, Lynen L, Calmy A, et al. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008; 22:2053-2067.
7. Long L, Fox M, Sanne I, Rosen S. The high cost of secondline antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24:915-919.
8. Humphreys EH, Chang LW, Harris J. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev 2010: 6:CD006517.
9. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
10. Riddler SA, Jiang H, Tenorio A, et al. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 2007; 12:531-541. (Pubitemid 47041152)
11. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148. (Pubitemid 41669003)
12. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Gugulethu, South Africa. S Afr Med J 2006; 96:315-320.
13. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776. (Pubitemid 44330743)
14. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88. (Pubitemid 46340429)
15. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009; 14:722-731.
16. World Health Organization. Treat 3 million by 2005: scaling up antiretroviral therapy in resource limited settings. A public health approach: World Health Organization; 2004. (Accessed 11 May 2011.) Available from http://www. who.int/hiv/pub/prev-care/en/arvrevision2003en.pdf
17. Department of Health South Africa. National antiretroviral treatment guidelines, Jacana 2004. (Accessed 11 May 2011.) Available from http://www.hst.org.za/uploads/files/ sa-ART-Guidelines1.pdf
18. Orrell C, Bekker LG, Wood R. Adherence to antiretroviral therapy - achievable in the South African context? S Afr Med J 2001; 91:483-484. (Pubitemid 32622040)
19. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva; 2009. (Accessed 11 May 2011.) Available from http://www. who.int/hiv/pub/arv/rapid-advice-art.pdf
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2006 revision). Geneva; 2006. (Accessed 11 May 2011.) Available from http://www.who.int/ hiv/pub/guidelines/artadultguidelines.pdf
21. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents 2007; 29:510-517. (Pubitemid 46562507)
22. Seyler C, Adje-Toure C, Messou E, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21:1157-1164. (Pubitemid 46763286)
23. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22:1305-1312.
24. ART-LINC of IeDEA Study Group, Keiser O, Tweya H, et al. Switching to second-line antiretroviral therapy in resourcelimited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867-1874.
25. Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15:251-258.
26. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health 2010; 15 Suppl 1:48-54.
27. Pasquet A, Messou E, Gabillard D, et al. Impact of drug stock-outs on death and retention to care among HIVinfected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS ONE 2010; 5:e13414.
28. Chalker J, Wagner A, Tomson G, et al. Urgent need for coordination in adopting standardized antiretroviral adherence performance indicators. J Acquir Immune Defic Syndr 2010; 53:159-161.
29. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for highburden countries. Antivir Ther 2009; 14:1039-1043.
30. L'homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23:863-865.
31. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369-1375. (Pubitemid 36819851)
32. Charles M, Noel F, Leger P, et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 2008; 86:970-977.
33. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500-506.
34. Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007-1012.
35. Castelnuovo B, John L, Lutwama F, et al. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic) 2009; 8:52-59.
36. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Secondline treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-518.
37. White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006; 11:155-163.
38. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixeddose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452. (Pubitemid 46147631)
39. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895. (Pubitemid 38553709)
40. Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
41. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
42. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
43. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597. (Pubitemid 351706742)
44. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
45. Muula AS, Ngulube TJ, Siziya S, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 2007; 7:63.
46. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
47. ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA), Keiser O, Anastos K, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-879.